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Editorial Comment
Enhanced Late Na Currents in Atrial Fibrillation
New Drug Target or Just an Epiphenomenon?*
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Tn this issue of the Journal, Sossalla et al. (1) present an
nteresting article on alterations of the Na current (INa) in
trial myocytes of patients with persistent atrial fibrillation
AF) and the effects of ranolazine, an orally active pipera-
ine derivative, on these currents. Although peak INa was
lightly lower in AF patients compared with patients in
inus rhythm (SR), the late and sustained component of the
urrent (INaL) was significantly larger (26%). The inhib-
tory effect of ranolazine on INaL was stronger in patients
ith AF compared with SR patients. Ranolazine also
uppressed premature atrial contractions in right atrial
See page 2330
rabeculae and reduced diastolic tension in these prepara-
ions. The authors conclude that dysregulation of INa might
e a mechanism contributing to AF. They also conclude
hat ranolazine exerts its antiarrhythmic effect at least partly
y inhibition of INaL, thereby suppressing triggered activity
nd improving diastolic dysfunction. The article touches
pon a number of interesting aspects of AF pathophysiology
hat are relevant for our understanding of ionic remodeling
ue to AF and its consequences for the identification of
rug targets interfering with Na and Ca2 homeostasis.
lterations of Na Handling in AF
ur current knowledge of alterations of Na homeostasis in
F is largely limited to alterations of Na ion currents or
ransporters. For example, there are clear indications for an
p-regulation of the Na/Ca2 exchanger (NCX) in human
F (2,3). In dogs, inhibition of the reverse mode of NCX
Ca2 entry) prevented electrical remodeling during short-
erm rapid atrial pacing, suggesting that Ca2 entry via
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oundation (2005.B112), and the Dutch Research Organization (NOW, VIDI-grant
16.086.379).everse-mode NCX contributes to early electrical remodeling
4). Reverse-mode NCX might lead to Na extrusion and
educed [Na]i.Measurements of Na
/K pump current (IP) in
uman AF showed no alteration in voltage dependence and
ensitivity to external [K], but sensitivity to [Na]i and the
ctual [Na]i was not determined (5). In animal studies, inhi-
ition of the Na/H exchanger was able to prevent electrical
emodeling during short-term rapid atrial pacing (6), suggest-
ng a role of increased Na loading in early electrical remod-
ling. INa has been measured by several authors in the setting
f AF or rapid atrial pacing. In canine models of AF, peak INa
as reduced, whereas a study performed in human atrial
yocytes reported no change (7,8).
The study by Sossalla et al. (1) adds new and important
ieces to this puzzle. They observe a 20% decrease in peak
Na in human AF, while the sustained INaL was enhanced by
6%. In an earlier study, the same group had shown that the
a2/calmodulin-dependent kinase II activates INaL (9).
he previously demonstrated increase in Ca2/calmodulin-
ependent kinase II expression and activity in human AF
3) might therefore have contributed to enhancement of INaL.
t remains unclear, however, to what extent the 26% increase of
NaL would increase [Na]i in atrial myocytes of patients with
F. Shortening of the action potential (electrical remodeling)
nd reduced peak INa will both tend to reduce [Na]i. Interest-
ngly, the only study to measure [Na]i in an AF model found
50% reduction of whole-cell and cytosolic [Na]i in dogs
ubjected to 48 h of rapid atrial pacing (10).
However, should future studies demonstrate enhanced [Na]i
n atrial myocytes of patients with AF, the findings of Sossalla
t al. (1) might become relevant for our understanding of the
lterations in intracellular signaling pathways associated with
F. Enhanced Na loading of atrial myocytes will tend to
ncrease Ca2 loading, which is a crucial step in pathways
nvolved in the electrical remodeling process and in hypertro-
hic and profibrotic responses. Thus, antagonizing Na load-
ng might delay or prevent the atrial remodeling process.
In contrast, the implications of the study on direct
roarrhythmic effects are much more difficult to appreciate.
he authors suggest that enhanced INaL might be an
additional mechanism for AF” by enhancing triggered
a
e
I
t
o
t
n
v
c
a
d
a
w
p
e
f
i
w
I
R
R
m
w
q
a
W
A
f
s
w
u
d
c
(
a
b
g
p
A
s
t
(

I
s
d
(
p
A
v
o
t
e
H
a
t
t
w
e
c
t
a
t
a
d
n
d
o
f
e
c
n
s
R
D
6
u
R
1
1
2344 Schotten et al. JACC Vol. 55, No. 21, 2010
Enhanced Late Na in AF May 25, 2010:2343–5ctivity in the atria (1). The question arises why the
nhanced propensity to triggered activity due to increased
NaL does not result in proarrhythmic events occurring in
he right atrial appendages. Focal discharges initiating AF
riginate from the sleeves of pulmonary veins, the ostia of
he coronary sinus and the caval veins, or the crista termi-
alis. Ectopy originating from the right atrial appendage is
ery rare. Thus, one must conclude that enhanced INaL
urrents in atrial myocytes isolated from right atrial append-
ges of patients with AF are not sufficient to produce focal
ischarges in vivo. In line with this, the rate of premature
trial contractions was even lower in AF patients compared
ith patients in SR. However, this does not exclude the
ossibility that in other regions of the atria, an even stronger
nhancement of INaL or enhanced INaL together with other
actors such as impaired intercellular coupling and reduced
nward rectifier currents might produce focal discharges,
hich then contribute to initiation or perpetuation of AF.
s the Antiarrhythmic Effect of
anolazine in the Atria Due to Block of Late INa?
anolazine has been proposed as an antianginal drug with
inimal effects on blood pressure and heart rate. In patients
ith chronic stable angina, ranolazine decreases the fre-
uency of recurrent ischemia and improves exercise toler-
nce (11). In the MERLIN–TIMI 36 (Metabolic Efficiency
ith Ranolazine for Less Ischemia in Non–ST-Elevation
cute Coronary Syndromes–Thrombolysis In Myocardial In-
arction 36) trial, ranolazine did not affect mortality, including
udden cardiac death over a period of 12 months in patients
ith non–ST-segment elevation myocardial infarction and
nstable angina (12). However, ranolazine reduced the inci-
ence of ventricular and supraventricular arrhythmias and
aused a trend toward a reduced incidence of new-onset AF
p  0.08) during the first 7 days of treatment.
Ranolazine has a complex profile of electrophysiological
nd metabolic effects. In normal, healthy hearts, it shifts the
alance between fatty acid and glucose oxidation toward
lucose metabolism, thereby improving oxygen efficiency,
ossibly contributing to improved myocardial function (13).
part from these metabolic effects, ranolazine also inhibits
everal ionic currents including INaL (inhibitory concentra-
ion of 50% [IC50] 6 M), IKr (IC50 12 M), the “late” ICa
IC50 50 M), INCX (IC50 91 M), peak ICa (IC50 296
M), and IKs (20% inhibition at 30 M), without affecting
to and IK1 (14). In atrial preparations, ranolazine produced
ignificant post-repolarization refractoriness. It slowed con-
uction velocity in atrial but not in ventricular preparations
15), especially at high rates. In atrial preparations and intact
igs, ranolazine reduced the stability of acetylcholine-induced
F (15). In myocardial preparations from canine pulmonary
eins, it suppressed triggered activity observed in the presence
f acetylcholine  isoproterenol (16).
In the current study, Sossalla et al. (1) report an inhibi-ion of the peak INa in atrial myocytes from SR patients,
1lucidating the earlier findings by Burashnikov et al. (15).
owever, in myocytes from AF patients, ranolazine did not
ffect peak INa. In contrast, ranolazine reduced INaL current
o a larger degree in AF than in SR patients. Interestingly,
his alteration in sensitivity between SR and AF patients
as associated with a shift from Nav1.5 to Nav1.1 subunit
xpression. In the light of altered Na channel subunit
omposition in AF patients, it will be important to inves-
igate whether ranolazine retains its particular class I anti-
rrhythmic effects (the atrium-specific reduction in conduc-
ion velocity, prolonged post-repolarization refractoriness,
nd decreased AF stability) in patients with AF.
Taken together, it remains to be investigated whether the
ecreased incidence of supraventricular tachycardias and
ew-onset AF during ranolazine treatment result from
irect effects on atrial electrophysiology, from improvement
f atrial metabolism, or from improvement of ventricular
unction, thereby indirectly reducing atrial arrhythmogen-
sis. Antagonizing enhanced Na loading in atrial myo-
ytes, however, certainly warrants further investigation as a
ew working principle to prevent atrial remodeling due to
tructural heart diseases or AF.
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epartment of Physiology, University Maastricht, P.O. Box 616,
200 MD Maastricht, the Netherlands. E-mail: Schotten@fys.
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